thymosin alpha-1
IMMUNOMODULATOR · THYMIC PEPTIDE · 28 AA
also: Tα1 · Ta1 · thymalfasin
Thymosin alpha-1 is a synthetic copy of a naturally occurring 28-residue thymic peptide, marketed as Zadaxin and approved in a number of countries outside the US and most of Europe, mainly for chronic hepatitis B and C and as a vaccine adjuvant. Its largest and most rigorous trial, a phase 3 study in sepsis, found no mortality benefit.
// our evidence grade — unedited
It is the only compound here with genuine marketing approval abroad and a properly powered phase 3 trial, but that trial (TESTS, n=1106) missed its primary endpoint and FDA found the evidence inadequate across all twelve conditions it reviewed.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | Thymalfasin (thymosin alpha 1), N-acetylated 28-residue thymic peptide |
| cas | 62304-98-7 |
| formula | C129H215N33O55 |
| molar mass | 3108.28 g/mol |
| purity | ≥ 99% HPLC |
| form | lyophilised powder, sealed vial |
| storage | Supplied as a white lyophilised powder stored at -20 °C for long-term laboratory holding; reconstituted solutions are kept at 2-8 °C for short-term use and are not intended for repeated freeze-thaw cycles. |
| solubility | Water-soluble; reconstituted in sterile water or aqueous buffer for laboratory work, with commercial vials supplied for reconstitution in sterile water. |
| sequence | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN |
// select size
crypto payment · research use only · not for human consumption
// others in Healing & Repair